欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:National Institutes of Health State of the Science Symposiu

发布时间:2025-05-17

National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis

Nora Ratcliffe, Nancy M. Dunbar, Jill Adamski, Daniel Couriel, Richard Edelson, Carrie L. Kitko, John E. Levine, Shanna Morgan, Jennifer Schneiderman, Steve Sloan, Yanyun Wu, Zbigniew M. Szczepiorkowski, Laura Cooling, for the American Society for Apheresis

 

The clinical use of extracorporeal photopheresis (ECP) for accepted indications such as graft-versus-host disease, transplant rejection, and cutaneous T-cell lymphoma continues to increase. Expanded applications for ECP, such as the treatment of select autoimmune diseases, are being explored. Extracorporeal photopheresis's capacity to both immunotolerize in the autoreactive setting, while immunizing against a lymphoma is unusual and suggestive of a unique mechanism. It is likely that ECP's induction of dendritic cells is key to its efficacy in both of these settings, but exactly how ECP impacts other immune components and their interactions is not fully understood. Further basic science research is necessary to elucidate how these dissimilar cellular activities are functionally integrated. On the clinical side, collaborative multicenter trials designed to recognize the principal variables controlling therapeutic responses and improve prognostic indicators may enable tailoring devices, treatment schedules, and doses to the needs of the individual patients or diseases. This review describes our current understanding of how ECP influences the immune system, reviews the existing clinical applications of ECP, and explores areas for future basic science and clinical research as presented at the National Institutes of Health State of the Science Symposium in Therapeutic Apheresis in November 2012.

 

上一篇:西亚试剂:揭秘罕见“跳跃基因”
下一篇:西亚试剂:张亚平等家犬嗅觉受体基因研究获进展
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4